Eutropics, Tolero Collaborate on CDx for Hematological Cancer Therapy | GenomeWeb

NEW YORK (GenomeWeb News) – Eutropics said today that it will use its companion diagnostic methodology to help Tolero Pharmaceuticals develop therapeutics for hematological malignancies.

Under the terms of the agreement, Eutropics will use its Praedicare-Dx biomarker platform to support the development of Tolero's alvocidibm, a Phase III compound that has demonstrated clinical activity in patients with acute myelogenous leukemia and chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.